8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
May 7, 2026·SEC
Personalis, Inc.(PSNL)Earnings, Financials & Key Ratios
PSNL•NASDAQ
$14.34
Price updated Jul 6, 2026
AboutPersonalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.Show more
- Revenue$0-100.0%
- EBITDA-$78M-36.1%
- Net Income-$81M
- EPS (Diluted)-0.91+33.6%
- ROE-35.02%+28.4%
PSNL Price & Volume
Personalis, Inc. (PSNL) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Challenges Operational Scalability Outlook
Investment Thesis • Updated 2026Q1
VerdictNegative: The company's inability to generate positive operating cash flow
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and capital exhaustion
Key Thesis Takeaways
- Personalis faces a precarious fundamental outlook characterized by significant revenue volatility and an inability to achieve operating leverage, as evidenced by a 24.9% year-over-year revenue decline in 2026Q1.
- While the company maintains a commitment to high-sensitivity MRD diagnostics, the aggressive R&D spend of $14.5 million—nearly matching quarterly revenue—continues to erode the equity base and deplete liquidity.
- Investors should monitor the company's ability to stabilize its project-based revenue model and manage its $63.4 million net PPE asset base, as current cash burn rates suggest a potential need for future capital market intervention.
Verdict Logic
evidenced by a -165.9% FCF margin in 2026Q1, suggests significant execution risk and ongoing capital exhaustion concerns.
PSNL Growth Metrics
Personalis, Inc. (PSNL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-24.71%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-13.66%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM20.93%
Return on Capital
10 Years-36.03%
5 Years-35.19%
3 Years-38.67%
Last Year-33%
PSNL Recent Earnings
Personalis, Inc. (PSNL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.29-26.1%
$0.23
Rev
$15M+6.8%
$14M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.26+16.1%
$0.31
Rev
$17M+1.7%
$17M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.24+14.3%
$0.28
Rev
$14M-14.9%
$17M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.23+8.0%
$0.25
Rev
$17M-14.5%
$20M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.29vs $0.23-26.1% | $15Mvs $14M+6.8% |
| Q1 2026 | Feb 26, 2026 | $0.26vs $0.31+16.1% | $17Mvs $17M+1.7% |
| Q4 2025 | Nov 4, 2025 | $0.24vs $0.28+14.3% | $14Mvs $17M-14.9% |
| Q3 2025 | Aug 5, 2025 | $0.23vs $0.25+8.0% | $17Mvs $20M-14.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Personalis, Inc. (PSNL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.34 | $1.27B | -15.76 | -100% | — | -35.02% | — | |
| $283.80 | $40.64B | -186.71 | 35.9% | -9.05% | -15.13% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $168.82 | $22.39B | -50.85 | 32.88% | -40.1% | — | — | |
| $99.93 | $6.22B | -76.87 | 20.32% | -19.85% | -17.46% | — | |
| $194.33 | $29.52B | 35.66 | -0.78% | 19.43% | 32.84% | — |
Compare PSNL vs Peers
Personalis, Inc. (PSNL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PSNL SEC Filings & Documents
Personalis, Inc. (PSNL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PSNL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PSNL Frequently Asked Questions
Personalis, Inc. (PSNL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Personalis, Inc.'s revenue?
Personalis, Inc. (PSNL) reported $64.5M in revenue for fiscal year 2025. This represents a 587% increase from $9.4M in 2017.
How fast is Personalis, Inc. growing?
Personalis, Inc. (PSNL) saw revenue decline by 100.0% over the past year.
Is PSNL profitable?
Personalis, Inc. (PSNL) reported a net loss of $95.6M for fiscal year 2025.
Dividend & Returns
What is PSNL's return on equity?
Personalis, Inc. (PSNL) has a return on equity (ROE) of -35.0%. Negative ROE indicates the company is unprofitable.
What is Personalis, Inc.'s free cash flow?
Personalis, Inc. (PSNL) had negative free cash flow of $84.6M in fiscal year 2025, likely due to heavy capital investments.